With the exception of the recent accelerated approval of aducanumab, in over 26 years of research and development (R&D) investment in Alzheimer's disease (AD), only five novel drugs—all for symptomatic treatment only—have reached FDA approval. Here, we estimate the costs of AD drug development during this period in the private sector.

中文翻译：

---

开发阿尔茨海默病治疗方法的成本：回顾性探索

除了最近加速批准 aducanumab 外，在超过 26 年的阿尔茨海默病 (AD) 研发 (R&D) 投资中，只有五种新药——均仅用于对症治疗——已获得 FDA 批准。在这里，我们估计了私营部门在此期间开发 AD 药物的成本。